FREE Daily Stock Alerts From Stock-PR.com
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced the appointment of Robert Martell, M.D., Ph.D., to its Board of Directors. Dr. Martell is currently the Director of the Neely Center for Clinical Cancer Research and the Leader of the Program in Experimental Therapeutics at the Tufts Medical Center Cancer Center as well as an Associate Professor of Medicine at the Tufts University School of Medicine. Curis also announced the retirement of Joseph M. Davie, M.D., Ph.D. from its board of directors.
Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics.
Read full article and disclaimer at : http://stock-pr.com/?p=20062